StemCells Says Achieved First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury

StemCells (Nasdaq: STEM) today announced that the first patient with an incomplete spinalcord injury has been enrolled in the Company's Phase I/II clinical trial inchronic spinal cord injury and transplanted with the Company's proprietaryHuCNS-SC^® neural stem cells. The patient, a Canadian man who suffered athoracic spinal cord injury from a sports-related accident, was administeredthe cells yesterday at Balgrist University Hospital, University of Zurich, aworld leading medical center for spinal cord injury and rehabilitation. Thisis the first patient in the second cohort of the trial, which will becomprised of four patients who retain some sensory function below the level oftrauma and are therefore considered to have an incomplete injury.